Reuters: TPG Explores $3 Billion Sale of Specialty Drugmaker Aptalis

TPG Capital LP has been exploring a sale of Aptalis Pharma, a specialty drugmaker it has owned since 2008 and values at more than $3 billion, sources told Reuters.

DealsNorth AmericaUSBriefs